Internal Medicine, Hematology & Oncology · Las Vegas, NV
NPI
1366441743
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
6827 W Tropicana Ave, 110
Las Vegas, NV, 89103
Phone (702) 508-9128
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.4M
181,005 services
Medicare patients, 2024
549
Average age 73
Drug cost, 2024
$8.8M
1,792 prescriptions
Company payments, 2025
$7,182
From 46 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Raja S Mehdi was code Q5125 (injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram), 20,280 times for 12 patients. In total Raja S Mehdi billed 181,005 services in 111 codes, and Medicare paid $3.4M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-01-10.
| Code |
|---|
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| Q5125 Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | Office | 20,280 | 12 | $0.37 | $7,530 |
| J0185 Injection, aprepitant, 1 mg | Office | 19,630 | 42 | $1.35 | $26K |
| J9263 Injection, oxaliplatin, 0.5 mg | Office | 16,788 | 13 | $0.06 | $934 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 16,400 | 19 | $44.80 | $735K |
| J9267 Injection, paclitaxel, 1 mg | Office | 15,072 | 18 | $0.08 | $1,205 |
| Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg | Office | 4,340 | 14 | $44.68 | $194K |
| J0897 Injection, denosumab, 1 mg | Office | 3,300 | 19 | $20.18 | $67K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 3,052 | 62 | $0.09 | $274 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,420 | 56 | $0.71 | $1,723 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,101 | 17 | $15.63 | $33K |
| J9190 Injection, fluorouracil, 500 mg | Office | 835 | 21 | $2.33 | $1,944 |
| M0010 Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | Office | 716 | 113 | $76.73 | $55K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 624 | 18 | $0.07 | $42.64 |
| J0640 Injection, leucovorin calcium, per 50 mg | Office | 562 | 18 | $3.58 | $2,009 |
| 36415 Venipuncture Blood Collection | Office | 538 | 297 | $8.62 | $4,638 |
By year: 2022 $2.1M for 162,427 services; 2023 $2.8M for 171,888 services; 2024 $3.4M for 181,005 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 538 | 297 | $8.62 | $4,638 |
Medicare prescription drug claims, 2024
In 2024, the drug Raja S Mehdi prescribed most often to Medicare patients was Letrozole, with 215 prescriptions and refills. In total Raja S Mehdi wrote 1,792 Medicare prescriptions that cost $8.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 215 | 373 | 96 | $2,511 |
| Prochlorperazine Maleate Generic | 183 | 185 | 135 | $4,974 |
| Ondansetron Odt Ondansetron | 145 | 145 | 119 | $3,463 |
| Xtandi Enzalutamide | 144 | 144 | 24 | $1.8M |
| Anastrozole Generic | 87 | 167 | 45 | $898 |
| Imbruvica Ibrutinib | 58 | 58 | Under 11 | $926K |
| Lupron Depot Leuprolide Acetate | 54 | 159 | 20 | $336K |
| Ibrance Palbociclib | 54 | 54 | Under 11 | $839K |
| Kisqali Ribociclib Succinate | 45 | 45 | Under 11 | $654K |
| Tamoxifen Citrate Generic | 45 | 95 | 24 | $790 |
| Revlimid Lenalidomide | 40 | 40 | 11 | $663K |
| Calquence Acalabrutinib Maleate | 39 | 39 | Under 11 | $595K |
| Dexamethasone Generic | 35 | 43 | 23 | $997 |
| Ondansetron Hcl Generic | 32 | 32 | 28 | $546 |
| Tagrisso Osimertinib Mesylate | 31 | 37 | Under 11 | $623K |
Brand drugs: 663 claims; generic drugs: 1,129 claims; opioid claims: 61.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Raja S Mehdi $7,182 ($6,542 in general payments such as food, travel and fees and $640 for research) from 46 companies. The largest payer was Daiichi Sankyo Inc. with $2,027.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 52 | $2,027 |
| Janssen Biotech, Inc. JNJ | 10 | $1,065 |
| Eli Lilly and Company LLY | 1 | $640 |
| AstraZeneca Pharmaceuticals LP AZN | 23 | $503 |
| Fennec Pharmaceuticals, Inc. FENC | 3 | $354 |
| Merck Sharp & Dohme LLC MRK | 12 | $287 |
| Pfizer Inc. PFE | 13 | $229 |
| Karyopharm Therapeutics Inc. KPTI | 3 | $172 |
| Caris MPI, Inc. | 3 | $172 |
| Sobi, Inc SOBI.ST | 5 | $148 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.